BioSpace News Archive

Allarity Therapeutics, Inc. announced that it received notice from the NASDAQ Stock Market that it was granted a hearing before a Nasdaq Hearings Panel.

Purple Biotech Ltd. today reported additional positive interim data from its randomized, controlled, open label, multicenter Phase 2 study (NCT 04731467) of CM24, in combination with Bristol Myers Squibb’s immune checkpoint inhibitor nivolumab and standard of care (SoC) chemotherapy, in second-line metastatic pancreatic ductal adenocarcinoma (PDAC).

Annovis Bio Inc. announced the filing of a provisional patent covering the manufacturing process of new solid forms of buntanetap.

60 DegreesPharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for infectious diseases, announced that the first patient has been enrolled in a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of tafenoquine in treating babesiosis in humans.

Cogent Biosciences, Inc. announced it has reached alignment with the U.S. Food and Drug Administration on the Company’s novel patient reported outcome measure, Mastocytosis Symptom Severity Daily Diary, for use in Part 2 of the registration-directed SUMMIT trial evaluating bezuclastinib in Nonadvanced Systemic Mastocytosis patients.

Tourmaline Bio, Inc. today announced the promotion of Ryan Robinson, CPA, to Chief Financial Officer and Treasurer, effective June 25, 2024.

GRI Bio, Inc. announced the pricing of a public offering of an aggregate of 2,185,793 shares of its common stock, Series C-1 warrants to purchase up to 2,185,793 shares of common stock and Series C-2 warrants to purchase up to 2,185,793 shares of common stock, at a combined public offering price of $1.83 per share and accompanying Series Warrants.

VolitionRx Limited, a multi-national epigenetics company, has issued a mid-year review to stockholders, ahead of its Annual Meeting of Stockholders to be held on July 2, 2024.

Bicara Therapeutics today announced the presentation of updated interim data from its ongoing, open-label Phase 1/1b dose expansion study of ficerafusp alfa (BCA101) at the 3rd Hawaii Global Summit on Thoracic Malignancies, taking place from June 25-29, 2024.

Healthcare technology company Komodo Health today announced the appointment of Julia Goebel as Chief Marketing Officer (CMO).